Highlights from INTERPHEX 2015
INTERPHEX 2015 is under way and Pharmaceutical Technology and BioPharm International are in the middle of the action!
INTERPHEX 2015 is under way and Pharmaceutical Technology and BioPharm International are in the middle of the action!
Pharmaceutical Technology, with its sister publication, BioPharm International, sponsored free educational sessions on tableting, continuous manufacturing, serialization, cell therapy manufacturing, and contract services. All sessions were presented in the exhibit hall.
Sessions held on Tuesday, April 21 included “Real-World Serialization: How Good is Your Game Plan?”; “Developments in Continuous Solid-Dosage Manufacturing”; and “Advances in Tableting”.
Outsourcing
On April 22, 2015 at 11AM, Jim Miller, founder and president of PharmSource Information Services, offered a review of the contract services landscape. Topics included the financial market conditions and consolidation in the CMO market, manufacturing capacity, pricing pressures, changing relationships with bio/pharma companies, and more.
Cell Therapy
At 1:15 PM, PharmTech and BioPharm presented “Succeeding in Cell Therapy Commercialization”. Experts from Lonza, NeoStem, Invetech, Pall Corp, and GE Healthcare discussed cell therapy issues and how to take a holistic approach from the earliest conceptual stage of any cell therapy project.
Visit PharmTech’s INTERPHEX 2015 page for all the latest from this year’s show!
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
